Cite
HARVARD Citation
Hiraoka, A. et al. (2023). Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib. Cancer medicine. pp. 325-334. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hiraoka, A. et al. (2023). Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib. Cancer medicine. pp. 325-334. [Online].